And a non-equity core commercial participant:

AstraZeneca, one of the world’s largest pharmaceutical companies.

The CRC also has a supporting commercial participant:

• Zimmer, the world’s leading orthopaedics company.

The aim of the CRC for Chronic Inflammatory Diseases is to understand the processes underlying serious chronic inflammatory diseases and to discover and develop better treatments to reduce the burden of these diseases.

Our research is working towards a healthier future for our community by improving the management of diseases like Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis (RA) and Osteoarthritis (OA).

Find out more about chronic inflammatory diseases

Our Cooperative Research Centre will establish a pipeline of intellectual property with significant potential for commercialisation. We attract top students and researchers as well as additional funding from government and other sources.

Find out about more how the CRC is managed

Interested in working for us?